Sugi Predict

Sugi Predict / Targets / VEGFA

VEGFA

Vascular endothelial growth factor A, long form · P15692 · VEGFA on Sugi Atlas →

26,544 patent compounds predicted against VEGFA, 14,533 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL273236 SCHEMBL273236 1.00 13/20
SCHEMBL278202 SCHEMBL278202 1.00 12/20
SCHEMBL278429 SCHEMBL278429 1.00 12/20
SCHEMBL273037 SCHEMBL273037 0.87 12/20
SCHEMBL272076 SCHEMBL272076 0.85 12/20
SCHEMBL272116 SCHEMBL272116 0.85 12/20
SCHEMBL271963 SCHEMBL271963 0.85 12/20
SCHEMBL273696 SCHEMBL273696 0.85 12/20
SCHEMBL277668 SCHEMBL277668 0.85 12/20
SCHEMBL272359 SCHEMBL272359 0.81 12/20
SCHEMBL272666 SCHEMBL272666 0.81 12/20
SCHEMBL272124 SCHEMBL272124 0.79 12/20
SCHEMBL271639 SCHEMBL271639 0.73 12/20
SCHEMBL273369 SCHEMBL273369 0.72 12/20
SCHEMBL277620 SCHEMBL277620 0.71 12/20
SCHEMBL272075 SCHEMBL272075 0.70 12/20
SCHEMBL273125 SCHEMBL273125 0.70 12/20
SCHEMBL272357 SCHEMBL272357 0.61 12/20
SCHEMBL273303 SCHEMBL273303 1.00 11/20
SCHEMBL272670 SCHEMBL272670 0.88 11/20

Clinical trials — most relevant to VEGFA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema PHASE4UNKNOWN
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Aflibercept and Bevacizumab for Diabetic Maculopathies PHASE4RECRUITING
Study EvAluating Genotypes While Using Lucentis 2 PHASE4COMPLETED
Intravitreal Macugen for Ischaemic Diabetic Macular Oedema PHASE4COMPLETED
Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity PHASE3UNKNOWN
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). PHASE3RECRUITING
Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration PHASE1/PHASE2COMPLETED
89Zr-RO5323441 PET Imaging in Glioblastoma PHASE2WITHDRAWN
Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma PHASE2COMPLETED
Study of Ramucirumab in Ovarian Cancer PHASE2COMPLETED
A Pilot Study of Bevacizumab for Neoplastic Meningitis PHASE1/PHASE2COMPLETED
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye PHASE2UNKNOWN
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery PHASE2COMPLETED
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma PHASE2COMPLETED
Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer PHASE1/PHASE2COMPLETED
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers PHASE2COMPLETED
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer PHASE2COMPLETED
A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia PHASE2WITHDRAWN
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) PHASE1COMPLETED
Vascular Endothelial Factor Gene Polymorphism in Preeclampsia nanCOMPLETED
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD) nanCOMPLETED
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis nanCOMPLETED
CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases nanCOMPLETED
Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction nanUNKNOWN
Effects of Early Vitamin A Supplementation on the Risk for Retinopathy of Prematurity in Extremely Preterm Infants nanCOMPLETED
Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab nanCOMPLETED
Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity nanUNKNOWN
Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration nanCOMPLETED
Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD) nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a VEGFA binder may also engage these)

ProteinNameSimilarity
Q00731 — 1.000 Q00731 →
PGF Placenta growth factor 0.993 landscape →
O76081 — 0.986 O76081 →
Q8N5Z5 — 0.983 Q8N5Z5 →
P79348 — 0.983 P79348 →
Q1ZZU3 — 0.983 Q1ZZU3 →
Q8K3V5 — 0.982 Q8K3V5 →
Q8WTX9 — 0.982 Q8WTX9 →
Q5IS69 — 0.982 Q5IS69 →
P28361 — 0.981 P28361 →
P15863 — 0.981 P15863 →
FGF2 Fibroblast growth factor 2 0.981 landscape →
Q8K3M5 — 0.981 Q8K3M5 →
P0C6A0 — 0.981 P0C6A0 →
P0C7X2 — 0.981 P0C7X2 →
Q6UYE1 — 0.981 Q6UYE1 →
Q5NRP8 — 0.980 Q5NRP8 →
Q12870 — 0.980 Q12870 →
Q9BTV7 — 0.980 Q9BTV7 →
P13207 — 0.980 P13207 →
Q8NAU1 — 0.979 Q8NAU1 →
O43541 — 0.979 O43541 →
Q5VZ18 — 0.979 Q5VZ18 →
Q15583 — 0.979 Q15583 →
Q12950 — 0.979 Q12950 →
Q8K4Z2 — 0.979 Q8K4Z2 →
Q765Z5 — 0.979 Q765Z5 →
Q9Y4B5 — 0.979 Q9Y4B5 →
P24097 — 0.979 P24097 →
Q8C1M2 — 0.979 Q8C1M2 →